These data are supported by the evidence that treatment with a small-molecule AMPK activator (GL-V9), which acts as an anti-inflammatory molecule on macrophages, triggers autophagy and NLRP3 degradation, providing a protective effect against colitis and CRC [172]. The gene discussed is NLRP3; the disease is colorectal carcinoma.